Investors & Media

Ionis announces positive results from fesomersen development program

–        Positive Phase 2b data from RE-THINC ESRD study of fesomersen in patients on hemodialysis presented at Kidney Week 2022 –        Ionis to regain rights to fesomersen from Bayer CARLSBAD, Calif. , Nov. 4, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc.

Read more
You are now leaving to visit